Cargando…
Roadblocks to success for RNA CARs in solid tumors
While CAR therapy has begun to demonstrate efficacy, cell-engineering techniques that result in permanent genomic modification carry several safety concerns. CAR expression driven by RNA creates a platform for delivery of highly-active cell therapy while avoiding long-term CAR-driven toxicity. Using...
Autores principales: | Singh, Nathan, Barrett, David M, Grupp, Stephan A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353174/ https://www.ncbi.nlm.nih.gov/pubmed/25964863 http://dx.doi.org/10.4161/21624011.2014.962974 |
Ejemplares similares
-
Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
por: Johnson, Abigail, et al.
Publicado: (2022) -
Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors
por: Mi, Juan, et al.
Publicado: (2022) -
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014) -
Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013) -
A new strategy to target regulatory T cells in solid tumors
por: Thomas-Schoemann, Audrey, et al.
Publicado: (2013)